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Abstract 
Background: Anemia is one of the most commonly observed hematological abnormalities and an independent 
prognostic marker of Human Immunodeficiency virus (HIV) disease progression in people living with HIV. 
However, there is limited evidence on the magnitude and its correlates among attendants of Antiretroviral 
Therapy (ART) in low-income countries including Ethiopia. Objective: The aim this study was to determine 
Prevalence of anemia and associated factors among PHIVs attendants Antiretroviral Therapy clinics in 
public health institutions in Dire Dawa Town, East Ethiopia Methods: An institution based cross - sectional 
study design was used from mid January to mid February 2014.The study participants were selected by using 
simple random sampling technique. A pre- tested structured questionnaire was used to collect data. Both 
bivariate and multivariable logistic regressions were used to identify associated factors. Hematological and 
immunological data were collected by using blood samples. Odds ratio along with 95% confidence interval was 
estimated to identify factors associated with anemia among the study population using a multivariable logistic 
regression. Results: The prevalence of anemia was 41.2%, 95% CI (36.7%, 45.9%). In multivariable logistic 
regression analysis, being female[AOR=1.95, 95% CI (1.22, 3.11)], use of different types of  zidovudine (AZT) 
based Highly Active Antiretroviral Therapy (HAART) : 1c:AZT+3TC+ neverapine [ AOR=2.56 , 95% CI 
(1.28,5.12) ] , and 1d: AZT+3TC + Evaferenz [ AOR=2.99 , 95% CI(1.27,7.03)] , overall ART category: 
zidovudine - based HAART  [ AOR=2.98, 95% CI (1.27,6.99)] ,  WHO’s HIV  clinical  stage III [AOR=2.49, 
95% CI: (1.24, 5.01)] and stage IV [AOR= 5.92, 95% CI (1.26, 27.8)] , and lower CD4 count [AOR=2.34, 95% 
CI (1.10,4.98)]  were  independently associated with anemia .Conclusion: Macrocytic anemia was common 
among patients taking Antiretroviral Therapy. The likelihood of developing anemia increases with disease 
progression associated decreased immunological state and use of zidovudin-based HAART. Therefore, those 
factors associated with anemia among PHIVs would be emphatically considered comprehensive care and 
treatment for PHIVs by including anemia treatment and prevention strategies by police makers in collaboration 
with others responsible bodies.  
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Introduction 
Hematological complications have been documented to be the second most common causes of morbidity and 
mortality among HIV sero-positive patients [1-3]. Anemia is one of the most commonly observed hematological 
abnormalities and independent prognostic marker of HIV disease progression in people living with HIV [4, 5]. 
 Available literatures have indicated that there is wide variation in the prevalence of anemia among 
HIV/AIDS patients across the world including Ethiopia. Accordingly, the level of anemia ranges from 10.1% to 
77.4% among patients using Highly Active Antiretroviral Therapy (HAART) [1, 6-15] in low- income countries. 
Few studies reported that macrocytosis or elevated Mean Cell Volume (MCV) is the common form of anemia 
which might be attributed to the effect of Zidovudine (AZT) regimen and deficiency of vitamin B12 or folate 
[16]. 
Anemia in HIV sero- positive people is also associated with  an impaired erythropoiesis resulting from 
the release of inflammatory cytokines and decreased production of hematopoietic growth factors coupled with 
malabsorption and impaired recycling of iron , malignant bone marrow infiltration and infection with malaria, 
helminthiasis, and  tuberculosis (TB) with the resultant hemolysis , gender, WHO’s HIV staging, low  CD4 
count ,  and opportunistic infection [9, 11, 16-19]. 
In Ethiopia, there is Paucity information on the prevalence and correlates of anemia among HIV 
patients on ART. Few studies reported inconsistently that there is association between anemia and use of 
Zidovudin (AZT) based ART among attendants of ART clinics without clear understanding of the typology of 
anemia and of available limited treatment options or categories to plan for the appropriate treatment category for 
the improvement of Hgb level among cohort of HIV patients. In some of the cases zidovudine –based ART was 
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found to be protective against anemia than being a risk factor [9-11, 20]. Therefore, this study was conducted to 
determine the prevalence of anemia and associated factors among ART users in the study area. 
 
Methods  
Study setting and design  
An Institutional based cross- sectional study design was conducted in Dire Dawa town from January 10 to 
February 10, 2014. In Dire Dawa town there are 12 health institutions that give ART services: one public 
Hospital, three private Hospitals and eight health centers. 
 
Study participants and sampling procedure  
The study participants were selected 425 HIV positive patients by using simple random sampling technique. A 
pre- tested structured questionnaire was used to collect data and at least had one visit in public health institutions 
in Dire Dawa town during the study period, was included in the study. However, HIV sero-positive pregnant 
women, who were on treatment for anemia in the last 3 months, patients on anti TB drugs and critically ill HIV 
positive patients were excluded. The sample size was computed using a single population proportion formula to 
estimate the prevalence of anemia with the following assumptions: prevalence of anemia among ART attendants 
to be 70% [9] , two sided alpha to be 1.96  , type I error and margin of error to be to be 5%  respectively yielding 
a sample size of  354 including a 10%  for non -  response  On the other hand ,  an   Open epi software was  used 
to determine the sample size for the difference between two population proportions to identify factors associated 
with outcome variable of interest  with the following assumptions : CD4 cell count was considered as an 
exposure  variable [9] to calculate the sample size with an estimated prevalence among the exposed (CD4 count 
between 350–500 cells/µL) to be  13% and among  unexposed (CD4 count greater than 500 cells/µL)  to be 4% , 
85% of power, ratio of sample size among  an unexposed/exposed: to be 1, risk/ prevalence ratio of 3.3 , risk/ 
prevalence difference of  9  to detect the odds ratio of 3.6  yielding a sample size of 425 including a  10% for  
non - response . To increase the power of the study the latter sample size was considered in this study.  
Samples were selected from nine public health institutions (one hospital and eight health centers) rendering ART 
services in the town. The hospital is automatically selected while three health centers were selected at random. 
The sample size was proportionally allocated to each health facility based on the profile of their ART attendants. 
Systematic random sampling was used to satisfy sample size allocation for facility. 
 
Measurements  
The questionnaire was adapted from Ethiopian Demographic and Health Survey document and other related 
published literatures.  It was initially prepared in English and translated to three local languages, “Afan Oromo, 
Amharic and Somali”, by fluent professionals of the respective languages by taking into account the major ethnic 
composition of the town and re-translated back to English to check for consistency. Data were then collected 
using an interviewer administered well structured and pretested questionnaire. Two diploma nurses who had 
training in ART and one senior laboratory technologist collected the data while one physician was recruited as a 
supervisor. Clinical and laboratory information including medical history, type of antiretroviral drugs 
consumption, and duration of antiretroviral therapy, hematologic (hemoglobin and red blood cell (RBC) 
morphology) and immunologic (CD4 cell count) parameters were determined for all of the study participants. 
Weight and height was measured by using measurement scale to assess body mass index (BMI) of the study 
participants. Some clinical information like the clinical staging of HIV and the regimen category that patient is 
taking was retrieved from the patients’ record. 
 Moreover, a volume of 3–5 ml venous blood in EDTA vacutainer tube was collected by data 
collectors from each participant and was sent to the laboratory. The blood sample was used for complete blood 
count, CD4 count determination and RBC morphology. Hematological parameters: hemoglobin (Hgb), mean 
corpuscular volume(MCV), mean cell hemoglobin(MCH), mean cell hemoglobin concentration(MCHC) and red 
cell distribution width(RDW) were determined using the automated blood analyzer CELL DYNE 1800 (Abott 
Laboratories Diagnostics Division) and CD4 count was measured using BD FACS count machine. 
 The standard operating procedures (SOPs) were followed during specimen collection and all other 
laboratory procedures. All reagents used were checked for their expiry date and prepared according to the 
manufacturer’s instructions to ensure the quality of laboratory data. 
In this study, anemia was understood as hemoglobin concentration (Hgb) less than 13 g/dl for males 
and less than 12 g/dl for females to indicate whether the patient is anemic or not based on WHO’s definition [21]. 
Age and  sex  of respondents ,  WHO’s clinical staging,  Type of HAART used  and HAART  category ,  
duration of ART use  in months , BMI  , CD4 cell count , and presence or absence of opportunistic infections  
were  independent variables of the study . 
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Statistical analysis  
Data were   first checked   for completeness manually and entered onto   EpiData version 3.11 for cleaning, and 
exported to SPSS version 16.0 computer software. Data were analyzed by using SPSS version 16.0 statistical 
packages and presented by frequencies and percentages for categorical variables and means and standard 
deviations for numerical variables. Bivariate analysis was conducted primarily to check the variables which had 
an association with the dependent variable individually. Variables associated with the dependent variables at p-
value <0.05 were then entered in to multiple logistic regression for controlling the possible effect of confounders.  
Adjusted Odds ratio along with 95% CI was estimated to identify factors associated with anemia. The results 
were presented using tables, figures and narratives. 
 
Ethical clearance  
The study was cleared from Haramaya University Institutional Research Ethics Review Committee. Then written 
consent was secured from health institutions to got permission. Verbal informed consent for participation was 
obtained from each study participants and the collected data were stored in a file, without the name of study 
participant and password protection of soft data and use of key and lock for hard copy data was employed to 
guarantee confidentiality. 
 
Results 
Socio - demographic characteristics 
A total of 425 ART clients were included in this study making a response rate of 100%. Two hundred seventy 
five (64.3%) of the participants were females and 177(41.6%) were Amhara by ethnicity.  One hundred ninety 
six (46.1%) of the participants were married and one hundred sixty nine (39.8%) were unemployed by 
occupation.  The mean age of the clients was 34 years with (SD±9) years. Two hundred six (48.9%) of the 
clients were found in the age range between 31 and 45. Among the respondents, 326 (76.7%) were orthodox 
Christian by religion followed by Muslims which constituted about 72 (16.9%). Eighty five (20%) of the 
participants had no formal education while 9 (2.1%) had education above 12 grades (Table 1). 
Table 1 : Socio-demographic characteristics of ART followers among public health institutions in 
DireDawa town, Eastern Ethiopia, during February, 2014 (n = 425) 
Variables   Number  Percentage (%)           
 Age (years) 
 
 
15-30   168 39.5 
31-45  206 48.5 
46-65  51 12.0 
Sex  Male 
Female 
150 
275 
35.3 
64.7 
Marital status Single  75 17.6 
Married  196 46.2 
Divorced  39 9.2 
Widowed 
Separated 
 57 
58 
13.4 
13.6 
Religion Orthodox   326 76.7 
Protestant  25 5.9 
Catholic 2 0.5 
Muslim  72 16.9 
Ethnicity Oromo 103 24.2  
Amhara 177 41.6 
Somali  34 8.0 
Tigray 65 15.4 
Harari 
Gurage 
39 
7 
9.2 
1.6 
Educational status No formal E 85 20.0 
Primary  240 56.5 
Secondary 
College  
91 
9 
21.4 
2.1 
Occupational  
 
 
 
 
 
 
 
Unemployed 
student 
Housewife 
169 
16 
56 
39.8 
3.8 
13.2 
House servant 
Daily laborer 
Merchant 
9 
74 
27 
2.1 
17.4 
6.4 
Government  employee 
Private employee 
45 
29 
10.5 
6.8 
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Clinical and immunologic characteristics of ART followers 
From a total of 425 study participants, 303(71.3%) and 58(13.6%) were in stage one and two of WHO clinical 
stage respectively and 194(45.6%) are taking zidovudine containing ART regimen (1c or 1d). Consequently, 
majority of the respondents had CD4 cell count greater than 500cell/µL 172(40.5%) while only 3(.7%) of the 
respondents had less than 50 cell/µL (Table 2). 
Table 2: Clinical and immunological characteristics of ART followers among public health institutions in 
DireDawa town, Eastern Ethiopia, during February, 2014 (n = 425) 
Variables   Number  Percentage (%)           
WHO ‘s  clinical 
staging  
 
 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
303 
58 
44 
20 
71.3 
13.6 
10.4 
4.7 
Type of ART 
 
 
 
1c 
1d 
1e 
1f 
146 
48 
169 
62 
34.3 
11.3 
39.8 
14.6 
CD4 cell 
 
 
 
 
 
>500 
350-500 
200-349 
100-199 
50-99 
<50 
172 
101 
105 
34 
10 
3 
40.4 
23.8 
24.7 
8.0 
2.4 
0.7 
BMI 
 
 
<18.49 
18.5-24.99 
>25 
101 
236 
88 
23.8 
55.5 
20.7 
ART duration in 
months 
 
 
3-20 
20-36 
36-60 
>60 
190 
94 
71 
70 
44.7 
22.1 
16.7 
16.5 
OI 
 
Yes 
No  
26 
399 
6.1 
93.9 
Regimen AZT user 
Non AZT user 
194 
231 
45.6 
54.4 
Prevalence of anemia among users of ART  
Participant’s Hgb level was used to determine the prevalence of anemia. Out of the total 425 respondents, the 
overall prevalence of anemia was 175 (41.2%). From the total anaemic individuals; 15(3.5%) and   160(37.6%)   
had   sever and mild to moderate anemia, respectively.  The type of anemia was determined using red cell indices 
values and macrocytosis (MCV>100 fl) was found to be more common, 25.6%. The mean SD) hemoglobin 
level of the study participants was 12.52 1.93) with slight difference between male and female participants 
(13.34 2.08) among male and 12.08  among females with the overall range of (18.8-3.9). The 
mean SD) MCV was 105.21 12.2) (Figure1). 
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Factors Associated with Anemia among ART Clients  
In bivariate analyses, age, sex, HAART category and duration of ART use, opportunistic infection, WHO’s 
HIV/AIDS clinical staging, BMI, and CD4 Cell count were associated with anemia at 0.2 confidence level. In 
multivariable logistic regression analysis, the odds of anemia were nearly twice higher among female 
participants [AOR=1.95, 95% CI: (1.22, 3.11)] compared with their counterparts, The odds of anaemia were  
nearly 3  times [AOR=2.99, 95% CI: (1.27, 6.99)] higher among users of zidovudine containing ART (1c = 
AZT+3TC+neverapine   ) and id = AZT+3TC +evaferenz   [AOR=2.56, 95% CI: (1.27, 6.99)] when compared 
with stavudine  (TDF)   based (1e and 1f) ART users ,  ART category;  zidovudine based HAART  [ AOR=2.98, 
95% CI (1.27,6.99)], WHO’s HIV  clinical staging ;  stage III [AOR=2.49, 95% CI: (1.24, 5.01)] and stage IV 
[AOR= 5.92, 95% CI (1.26, 27.8)]  and  CD4 cell count of  less than 200  [AOR=2.34, 95% CI (1.10,4.98)]  
were significantly associated with anemia (Table 3). 
Table 3:  Factors associated with anemia among ART users from public health institution of Dire Dawa 
town, Eastern Ethiopia, during February, 2014. (n=425). 
Variables           Anemia COR (95%CI) AOR and 95%CI 
Yes      No  
  
Age (Years) 15-30 73 (17.2%) 95 (22.4%) 1.0 1.0 
31-45 
46-65 
76 (17.9%) 
26 (6.1%) 
130 (30.6%) 
25 (5.9%) 
.761(.502, 1.153) 
1.353(.72,2.536) 
.895(.563, 1.42) 
1.53(.769,3.04) 
Sex Male 52(12.2%) 98 (23.1%) 1.0 1.0 
Female  123 (28.9%) 152 (35.8%) 1.52 (1.01, 2.30) 1.95(1.22, 3.11)* 
Type of ART 1c 
1d 
1e 
1f 
73(17.2%) 
26(6.1%) 
59(13.9%) 
17(4) 
73 (17.2%) 
22(5.2%) 
110(25.9%) 
45(10.6%) 
2.64 (1.38,5.05) 
3.13(1.41,6.94) 
1.42(.74,2.69) 
1.0 
2.56(1.28,5.12)* 
2.99(1.27,7.03)* 
1.11(.55,2.23) 
1.0 
OI No 156(36.7%) 243(57.2%)  1 1 
Yes 19(4.5 %) 7(1.6%) 4.23(1.74,10.29) 1.42(.39, 5.11) 
WHO’s clinical  
staging  
Stage 1 109(25.6%) 194(45.6%) 1.0 1.0 
Stage 2 23(5.4%) 35(8.2%) 1.17 (.66, 2.08) .93(0.49, 1.76) 
Stage 3 27(6.4%) 17(4%) 2.83(1.48, 5.42) 2.49(1.24, 5.01)* 
Stage 4 16(3.8%) 4 (.9%) 7.12(2.32, 21.83) 5.92(1.26, 27.8)* 
ART duration in 
Months 
3-20 
20-36 
75(17.6) 
39(9.2%) 
115(27.1) 
55(12.9%) 
1 
1.09(.66,1.80) 
1 
1.34(.77,2.46) 
36-60 30(17.1%) 41(16.4%) 1.12 (.65,1.96) 1.08(.57, 2.06) 
>60 31(7.3%) 39(9.2%) 1.22(.70,2.121) 1.62(.83, 3.18) 
BMI <18.49 51(12%) 50(11.8%) 1.88(1.04,3.37) 1.68(.87,3.23) 
18.5-24.99 93(21.9%) 143(33.6%) 1.19 (.72,1.99) 1.10(.62,1.93) 
>25 31(7.3%) 57(13.4%) 1 1 
CD4 cell count 
 
 
 <200 27(6.4%) 21(4.9%) 2.18 (1.14,4.18) 2.34(1.10,4.98)* 
200-500 
>500 
85 (20%) 
63(36%) 
122 (28.7%) 
107(42.8%) 
1.18(.78,1.79) 
1 
1.27(.79,2.03) 
1 
ART category AZT user. Non 
AZT user. 
99(23.3) 
76(17.9) 
95(22.4) 
155(36.5) 
2.12(1.43,3.14) 
1 
2.98(1.27,6.99)* 
1 
* = p ≤  0.05 ,    AOR= Adjusted Odds Ratio , BMI = Body Mass Index , COR = Crude Odds Ratio ,  OI= Opportunistic Infection , 1c= 
AZT+3TC+neverapine  ,  1d = AZT+3TC + evaferenz  ,  1e =  TDF+3TC+evaferenz  , 1f=  TDF+3TC+neverapine     
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Discussion 
The prevalence of anemia is less than half among the study population in which macrocytic anemia is more 
common. In multivariable analysis, sex of the participant, use of different types of zidovudine (AZT) containing 
HAART, ART category, CD4 cell count, and WHO clinical staging remained independent factors associated 
with of anemia.  
In this study prevalence of anemia (41.2%) is less when compared with results of studies from 
different regions including Ethiopia [6, 8, 9]. This might be attributed to difference in the definition of anemia 
used;   anemia was defined as hemoglobin level less than 12g/dl for both male and female participants in these 
studies while it was understood as Hgb concentration less than 13 g/dl for males and less than 12 g/dl for females 
in the present study. However, our finding is almost all similar with other studies conducted previously [1, 7]. 
This similarity could be due to similarity of the study  participants in both  cases and of  operational definition  
used to define  anemia . 
Gender difference in terms of proportion and severity of anemia was observed in this study. Females 
were found to be more likely anemic and develop severe anemia compared with males study participants. The 
odds of anemia were nearly twice among female participants compared with their counterparts. The level of mild 
to moderate anemia (37.6%) in this study was lower when compared with other studies while  the observed 
degree of severity (3.5%)  is comparable with some previous  studies [6, 9]. This could be due to  difference in 
the definition of anemia in the respective studies. 
In this study macrocytic anemia (MCV>100 fl )  is more common .The odds having anemia among 
patients who were taking a zidovudine based - HAART  regimen such as  AZT, 3TC and neverapine and AZT, 
3TC and evaferenz is nearly three times higher  compared with patients who were taking stavudine based 
regimen. Other studies have also indicated that  macrocytosis is typically associated with cyanocobalamine  or 
folate deficiency [16] and use of zidovudine (AZT) based HAART  than stavudine –based regimen [8, 11, 16, 17, 
20, 22, 23]. The commonness of  macrocytic anemia  among HAART clients  might indicate that anemia in ART 
users  is more likely  attributed to use of AZT based HAART due to the myelosuppressive effect of zidovudine 
causing morbidity and increasing treatment cost  than  anemia in the general population which is often attributed 
to iron deficiency . Moreover, lack of significant association between body mass index of the study participants 
and anemia could also suggest that iron deficiency anemia is less likely in this study population.  
However, according to reports from different setting of Ethiopia, there are contradicting evidence with 
this regard that not all  AZT combined  ART  do not increase the risk of anemia . One  study indicated that the 
use of  both evaferenz and nevirapine  combined  AZT can end up in  anemia and other complications  [20] 
while another study reported that only  evaferenz combined AZT was independently positively associated with 
greater risk  developing  anemia than  patients  taking  neverapine combined AZT which has got protective effect  
[10]. It was also noted that use of HAART for 12 months or more was associated with a protective effect against 
development of anemia [24] .It seems that the selection of appropriate regimen for the patients  is  still difficult  
and requires further  attention  by initiating  large scale study to  make  more evidence based decision on the 
selection of  conducive  treatment  approach. 
It was found that participants in WHO’s stage III and IV of AIDS staging were four times more likely 
to develop anemia than asymptomatic patients. In agreement with the   finding of this study   ,in other similar 
previous studies,  it was identified that although anemia occurs at  all stages of HIV/AIDS ,  its  prevalence and 
severity tends to rise with disease progression that is stage III and  IV [17, 25, 26]. This could be explained by 
the fact that viral load  is so high during late stage of the disease  impaiing   the process of erythropoiesis 
resulting in decline in the level of  Hgb during this period of time.  
Anemia was also associated with CD4 lymphocyte count < 200 cells/µL compared with a CD4 
lymphocyte count > 500 cells/µL which shows that the risk of anemia is higher with more advanced stage of 
HIV infection. This finding confirmed the findings of prior studies in which low CD4 count has been associated 
with the occurrence of anemia among users of ART regardless of other factors like WHO’s clinical staging [5].  
This could also be explained by deterioration in the formation of Hgb due to disrupted erythropoiesis resulting 
from the release of inflammatory cytokines and decreased production of hematopoietic growth factors coupled 
with malabsorption and impaired recycling of iron substance secondary to HIV/AIDS. 
On this research by considering the main strength of this research lies on its laboratory based study 
which were generalizable to this populations  and its limitations. One is that the study was not able to identify 
anemia due to deficiency of ferreting and iron binding capacity, micronutrient deficiency like folate, vitamin B12 
(cobalamine), and bone marrow depression. The other is that like any measurement Hgb determination might be 
affected   due to error inherent in Hgb determining machine and   the measurer although all possible cautions 
have been taken into account before data collection to overcome such problems.  
 
Conclusions 
In this study microcytic anemia is more common than normocytosis and microcytosis indicating the effect of 
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zidovudine rather than iron deficiency anemia among the study population.  Female gender, use of efaferenz and 
nevarapine combined AZT, late stage of HIV/AIDS, and lower CD4 count were independently impacted the 
development of anemia.  
Health professionals need to routinely investigate and treat hematological abnormalities before and 
after initiation of ART to improve the quality of life for HIV patients.  
Policy designers and planners should also work on the identification of strategies that reduce morbidity 
and mortality from anemia related to ART use and scale –up research in the area of HAART administration for 
HIV patients and further causes of anemia among such cohort of population. 
Therefore, those factors associated with anemia among PHIVs would be emphatically considered 
comprehensive care and treatment for PHIVs by including anemia treatment and prevention strategies by police 
makers in collaboration with others responsible bodies.  
It would be better to give great emphasis on plan to reduce and treat microcytic anemia among these 
population.  
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